Lexeo Therapeutics’ Post

Dear Colleagues, A recent publication in the American Journal of Case Reports by authors from Charles University, Prague, Czech Republic, reports the association between non-compliant therapy for congenital adrenal hyperplasia (CAH) and the development of adrenal tumors. The case report highlights the extreme enlargement of adrenal glands in a 42-year-old woman who discontinued therapy during adolescence. The multidisciplinary team recommended the bilateral removal of giant myelolipomas. The findings reinforce the suspected link between non-compliant CAH therapy and the promotion of adrenal tumor growth. This report underscores the importance of adhering to medical treatment guidelines for CAH patients to prevent serious complications. The complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/gj7fQd-c

Dear Colleagues, A recent publication in the American Journal of Case Reports by authors from Charles University, Prague, Czech Republic, reports the association between non-compliant therapy for congenital adrenal hyperplasia (CAH) and the development of adrenal tumors. The case report highlights the extreme enlargement of adrenal glands in a 42-year-old woman who discontinued therapy during adolescence. The multidisciplinary team recommended the bilateral removal of giant myelolipomas. The findings reinforce the suspected link between non-compliant CAH therapy and the promotion of adrenal tumor growth. This report underscores the importance of adhering to medical treatment guidelines for CAH patients to prevent serious complications. The complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/gdpaiVWA

B cell depletion is one of the most efficient treatment regimen in #multiplesclerosis, yet its clinical efficacy remains largely enigmatic. In our recent study led by Can Ulutekin and Galli Edoardo at the Becher lab of the University of Zurich we performed longitudinal profiling of MS patients undergoing B cell depletion. We uncovered B cell/T cell interactions mediated by the CD27/CD70 axis as potential driver of the clinical efficacy of B cell depleting therapies. Many thanks to all our valuable collaborators and the patients that donated samples for this study! Paper: https://lnkd.in/eWP_aU_k X-torial: https://lnkd.in/eK2SuGeE

Emerging new bio markers in Thoracic Transplantation ❤️🫁have the potential to change how we treat our patients. Find out more about how to use them in this new consensus statement from ESOT - European Society for Organ Transplantation #heart #lung #transplantation #hearttransplantation #lungtransplantation

$INMB $7.24 +0.26. DAC $6.55 (4.5.23). CHANGE EXIT TO LEGACY FROM 9.00. INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference (6.98) An in-depth analysis of MRI gray matter microstructure following treatment with XPro™ shows that the greatest improvement was in the earliest and most affected regions of the AD brain; an effect that was accompanied by an improvement in neuronal proteins and EEG changes associated with core AD pathologies.

Day 1 of the #EVForum is underway! We've had a fantastic morning of presentations focusing on #Biomarkers #Diagnostics and #liquidbiopsies and our first panel discussion of the day with Naveed Akbar costanza emanueli Michiel Pegtel romaric lacroix: How can EV Assays reach Clinical Practice? 🔹 what are the current limitations for EV assays to reach clinical practice 🔹 What are the most promising clinical applications of EV as biomarkers in the cardiovascular field? 🔹 How to standardize an EV assay? #Extracellularvesicles

Excellent study highlighting the need for Tau biomarkers .

A study was done in a prospective tertiary cohort with CLD, to assess clinical performance against liver biopsy of different Noninvasive methods (NIMs) : 1.For advanced and bridging fibrosis: LIVERFASt Fibrosis test, Enhanced liver fibrosis score (ELF), FIB-4 and LSM using vibration controlled transient elastography (VCTE). 2.For steatosis (mild, moderate and marked): LIVERFASt Steatosis test and CAP (Fibroscan) in NAFLD patients, including a control group with CLD without steatosis (S0)]. Conclusion: • LIVERFASt can be an alternative to imaging methods for stratifying patients with NAFLD and NASH. • LIVERFASt is a blood biomarker for fibrosis and steatosis staging fibrosis and steatosis with similar performances to VCTE/CAP in patients with CLD. • LIVERFASt and VCTE outperformed ELF for staging advanced liver fibrosis. #liverfast #fibronosticsstudies #NAFLD #NASH Find out more https://lnkd.in/guJqrVEy

#millimeterwaves #Glioblastoma The potential effects of a 30.5 GHz CW signal for therapeutic purposes in GBM. https://lnkd.in/dM6v4VCS

In idiopathic pulmonary fibrosis, CXCL6 is involved as a profibrotic mediator in the complex crosstalk between ectopic epithelial cells and fibroblasts. Elevated levels are linked to high mortality rates, suggesting CXCL6 as a new biomarker and a potential therapeutic target. https://bit.ly/3uNkQe1